Myrosor (Ezetimibe, Rosuvastatin)

Ezetimibe/rosuvastatin, the active ingredient in Myrosor, is a statin and cholesterol absorption inhibitor presented as a tablet for oral use. It lowers LDL‑C and total cholesterol in adults with hypercholesterolemia or mixed dyslipidemia. GNH USA supplies Myrosor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Myrosor is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways. - Hypercholesterolemia: reduces elevated LDL‑C and total cholesterol levels. - Mixed dyslipidemia: improves the overall lipid profile by lowering LDL‑C and triglycerides while raising HDL‑C. - Primary prevention of cardiovascular events: helps lower risk in patients with high cholesterol who have additional risk factors.

Adverse reactions may occur with Myrosor and should be monitored.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhea. - Elevated liver enzymes: transient increases in ALT/AST. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Acute hepatitis: marked elevation of liver enzymes with jaundice. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Renal impairment: worsening kidney function in susceptible patients. - Myopathy with statin‑related muscle toxicity.

Before prescribing Myrosor, clinicians should consider several safety aspects. - Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Renal function assessment: evaluate creatinine clearance in patients with kidney disease. - Drug interactions: review concomitant medications that affect statin metabolism. - Pregnancy and lactation: avoid use due to unknown safety profile. - Patient education: advise reporting unexplained muscle pain or weakness. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Myrosor may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase rosuvastatin exposure. - Cyclosporine: markedly raises rosuvastatin levels, raising risk of myopathy. - Gemfibrozil: enhances statin‑related muscle toxicity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption. - Warfarin: potential alteration of INR, requiring monitoring. - Niacin: may increase risk of liver enzyme elevations.